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Systemic interleukin 12 displays anti-tumour activity in
the mouse central nervous system
H Kishima, K Shimizu, Y Miyao, E Mabuchi, K Tamura, M Tamura, M Sasaki and T Hayakawa
Department of Neurosurgery, Osaka University Medical School, Osaka 565-0871, Japan
Summary In various systemic cancers, interleukin 12 (IL-12) induces anti-tumour immunity mediated by T lymphocytes and natural killer
cells. To determine whether IL-12 has anti-tumour activity against malignant gliomas in the central nervous system (CNS), which is
considered to be an immunologically privileged site, we treated mice with meningeal gliomatosis by intraperitoneal (i.p.) or intrathecal (i.t.)
administration of recombinant murine IL-12. Although untreated mice revealed symptoms, such as body weight loss or paraplegia as a result
of the meningeal gliomatosis within 8 days after tumour inoculation, 80% of the mice treated with IL-12 at 0.5,g i.p. were cured. Many
lymphocytes, mostly CD4+ and CD8+ cells, infiltrated to the tumours of IL-12-treated mice. The numbers of these cells increased in the
cervical lymph nodes, into which the cerebrospinal fluid drains, and there they secreted a considerable amount of interferon-y. Mice cured by
IL-12 rejected subcutaneous or i.t. rechallenge with their original glioma cells, but the same mice were not able to reject other syngeneic
tumour cells. These results indicate that the immune system recognizes malignant glioma cells in the subarachnoid space of the CNS and
that systemic IL-12 may produce effective anti-tumour activity and long-lasting tumour-specific immunity.
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The central nervous system (CNS) has long been considered to be
an immunologically privileged site (de Micco, 1989), as the
blood-brain barrier (BBB) had been thought to prevent compo-
nents of the immune system from entering. Recently, several
immunological reactions have been reported to take place in the
CNS. For instance, T lymphocytes infiltrate the CNS in several
disease models (Fontana et al, 1987), some glial cells express major
histocompatibility complex (MHC) antigens (Frank et al, 1986;
Fontana et al, 1987), microglia are derived from bone marrow
(Hickey et al, 1992), and cytokine networks exist in the CNS
(Fontana et al, 1984). Among gliomas, which account for 35% of
all primary CNS tumours (Annegers et al, 1981), glioblastomas are
the most frequent and intractable tumours (Nazzaro et al, 1990;
Yoshida et al, 1994). Less than 10% of glioblastoma patients
survive longer than 5 years despite radical surgeries and various
adjuvant therapies (Nazzaro et al, 1990; Yoshida et al, 1994). The
rest of the patients usually suffer from progressive tumour growth
and, less frequently, meningeal dissemination. Various types of
immunotherapy, such as cytokine therapy, antibodies and adoptive
immunotherapy, have been tried in malignant glioma patients
(Shimizu et al, 1987; Barba et al, 1989; Nitta et al, 1990; Lillehei et
al, 1991; Farkkila et al, 1994), sometimes showing a therapeutic
effect without significantly prolonging survival.
Interleukin (IL) 12 has been cloned, and recombinant IL-12 has
exhibited interesting biological effects in vivo and in vitro
(Kobayashi et al, 1989; Wolf et al, 1991; Schoenhaut et al, 1992).
IL- 12 stimulates natural killer (NK) cells, lymphokine-activated
killer (LAK) cells, cytotoxic T-lymphocyte (CTL) and T-helper
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(Th)-1 cells to secrete interferon-y(IFN-y) (Stern et al, 1990; Chan
et al, 1991; Seder et al, 1993; Brunda, 1994; Gately et al, 1994;
Kennedy et al, 1994). In murine models, IL-12 has shown potent
anti-tumour activity (Brunda et al, 1993, 1994; Nastala et al, 1994;
Mu et al, 1995), which is reportedly dependent upon IFN-y
secreted by Th1 or NK cells, enhancement ofCD8+ T lymphocytes
or CTL, induction ofCD3+ NK cells in the liver and the activation
of tumour-infiltrating lymphocyte (TIL) (Andrews et al, 1993;
Brunda et al, 1993; Bloom et al, 1994; Nastala et al, 1994; Cesano
et al, 1995; Hashimoto et al, 1995). Adoptive immunotherapy and
gene therapy using IL-12 have also been reported in some models
(Andrews et al, 1993; Tahara et al, 1994, 1995; Martinotti et al,
1995; Zitvogel et al, 1996). However, little evidence has been
reported with regard to the efficacy of IL-12 against brain tumours
in vivo.
In advanced phases of human glioblastoma, some tumours
undergo cerebrospinal fluid (CSF) pathway dissemination or
meningeal gliomatosis (MG) (Arita et al, 1994). The MG model
used in the present experiments effectively mimics the terminal
state of such patients. Using this model, we demonstrated that
systemically administered IL-12 produces a potent anti-tumour
effect and long-lasting immunity in the CNS by promoting the
proliferation ofTIL and by stimulating local IFN-yproduction.
MATERIALS AND METHODS
Cell lines
RSV-M mouse glioma cells (Kumanishi et al, 1973) and C3H/MCA
clone 15 fibrosarcoma cells (Rapp et al, 1975) derived from
C3H/HeN mice were maintained in Dulbecco's modified Eagle
medium (DMEM) with 10% heat-inactivated fetal bovine serum
(FBS) in a humidified 10% carbon dioxide-in-air atmosphere at
37°C. C3H/MCA clone 15 fibrosarcoma cells were purchased from
the Institute for Fermentation, Osaka (IFO, Osaka, Japan).
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Figure 1 Tumours in the brain of meningeal gliomatosis (MG) mice. RSV-M
glioma cells (5 x 106) were inoculated intrathecally into C3H/HeN mice.
Tumour formation was observed in the basal cistern. A, Three days after
tumour inoculation; B; 8 days after tumour inoculation. Haematoxylin and
eosin (H and E) staining. Magnification x 20
Glioma models and in vivo IL-12 treatment
RSV-M glioma cells were harvested with 0.25% trypsin and
washed three times with PBS (137 mm sodium chloride, 2.7 mM
potassium chloride, 8.1 mM disodium hydrogen phosphate and
1.5 mm potassium dihydrogen phosphate). The cells were
suspended in PBS at a concentration of 108 cells ml. An MG
model was produced in 7-week-old female C3H/HeN mice
weighing 18-21 g by inoculating 50 gl of the cell suspension into
the cistema magna using a 26-gauge needle. An MG model was
also produced in 7-week-old female BALB/c-nu/nu mice by inoc-
ulating 5 x 106 cells as described above. Recombinant murine IL-
12 (rmIL-12) (Hoffmann-La Roche, Nutley, NJ, USA) (Gately et
al, 1994) was diluted in PBS and injected intraperitoneal (i.p.) (0.5
or 0.1 gg 200 il-') or intrathecal (i.t.) (0.5, 0.1 or 0.02 gg 50 gt1')
into the C3H/HeN mice and i.p. (0.5 gg 200 ,ul-') into the
BALB/c-nu/nu mice once daily from days 3 to 7 after tumour
inoculation. When MG mice revealed physical symptoms, such as
20% body weight loss or paraplegia (MG symptoms), we killed
them to confirm the tumour formation histologically. Each group
consisted of five mice, and all experiments were repeated more
than twice. Differences in days without MG symptoms between
the treated groups and the control group were determined using
Student's t-test. Animals were handled in accordance with the
guidelines of the Animal Committee of Osaka University Medical
School and UKCCR guidelines for the welfare of animals in
experimental neoplasia (UKCCR, 1988).
Histology and immunohistochemistry
MG mice which had been treated with rmIL-12 at 0.5 jg i.p. and
untreated controls were killed on days 4, 6 and 8 after tumour inoc-
ulation. The brain was removed, immediately frozen and embedded
in OCT compound (Tissue Tek, Miles, Elkhart, IN, USA). Coronal
sections were cut at a thickness of 7 gm using a cryostat, fixed in
acetone for 15 min and then stained with biotinylated rat mono-
clonal antibody (MAb) against T-lymphocyte antigens CD4 and
CD8 (PharMingen, San Diego, CA, USA). Other sections were
stained with haematoxylin and eosin (H and E).
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Figure 2 Anti-tumour effect of IL-12 against glioma in immunocompetent mice. (A) C3H/HeN mice were treated once daily with rmlL-12 intraperitoneal (i.p.)
for 5 days (0.5 pg, bold solid line; 0.1 pg, dashed line) or left untreated (thin solid line). Arrows indicate rmlL-12 administration. Statistical evaluation by
Student's t-test. *P= 0.053, **P < 0.01. (B) C3H/HeN mice were treated once daily with rmlL-12 intrathecal (i.t.) for 5 days (0.5pg, bold solid line; 0.1 gg, bold
dashed line; 0.02 9g, thin dashed line) or left untreated (thin solid line). Arrows indicate rmlL-12 administration. Statistical evaluation by Student's t-test.
*P = 0.13, **P = 0.072, ***P = 0.078
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Cell staining and flow cytometry of lymphocytes
The spleen and cervical lymph node (CLN) of MG mice which
had been treated with rmIL-12 at 0.5 ,ug i.p. were immediately
removed after the animals were killed. Untreated MG mice were
used as controls. The CLN and spleen were suspended mechani-
cally in PBS. Cells remaining after the lysing of red blood cells
were washed twice and counted (Hashimoto et al, 1995). Spleen
cells (106) were incubated with FITC- or PE-conjugated MAb
against mouse lymphocyte antigens CD3, CD4 and CD8
(PharMingen), and were analysed by FACScan (Becton
Dickinson, Mountain View, CA).
IFN-y and IL-10 secretion
Lymphocytes (106) from the CLN and splenocytes (106) were
cultured in 250,l of complete medium (10% heat-inactivated
FBS, 50glM 2-ME, 20 mM HEPES, 110gg ml-' sodium pyruvate,
2 mM L-glutamate and approximate concentrations of non-essen-
tial amino acids in RPMI1640) for 48 h. The culture medium were
then collected and stored at -20°C until measurement ofIFN-yand
IL-10 concentrations using ELISA kits purchased from Genzyme
(Cambridge, MA, USA).
Tumour rechallenge in MG mice cured by IL-12
RSV-M glioma cells (5 x 106) or syngeneic C3H/MCA clone 15
fibrosarcoma cells (5 x 106) were reinoculated into the cistema
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Figure 3 Anti-tumour effect of IL-12 against glioma in T-cell-deficient mice.
BALB/c-nu/nu mice were treated with rmIL-12 at 0.5 ,ug i.p. once daily for 5
days (bold line) or left untreated (thin line). Statistical evaluation by Student's
t-test. *P= 0.17
magna of five MG mice which had received rmIL-12 i.p. and
survived over 8 weeks. Other long-surviving MG mice after rmIL-
12 i.p. were reinoculated subcutaneously (s.c.) with 107 RSV-M
glioma cells or C3H/MCA clone 15 fibrosarcoma cells. Diameters
of s.c. tumours were measured with callipers, and the volume was
calculated using the formula: volume = (longest diameter) x
(shortest diameter)2 x 1/2. All mice were 15-18 weeks old at the
second tumour challenge.
a
Figure 4 Representative histology and immunohistochemistry of tumours and surroundings. Mice were killed 6 days after the inoculation of RSV-M glioma
cells; the treated group was given rmlL-12 at 0.5 ,ug i.p. once daily beginning on day 3 after tumour inoculation. (A) Tumour area in an untreated mouse (H and
E staining; magnification x 200), showing few lymphocytes. (B) Tumour area in a mouse treated with IL-12 at 0.5 gg i.p. (x 200), many infiltrating lymphocytes
and a few necrotic areas seen in and around the tumour. (C) Immunohistochemically stained section adjacent to B, using MAb directed against CD4 (x 200),
with many CD4+ lymphocytes being visible. D: Immunohistochemistry of section adjacent to B, using mAb directed against CD8 (x 200), with many CD8+
lymphocytes being seen. The T4/T8 ratio was approximately 0.4-0.6
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RESULTS
Tumour formation was observed in the CNS of MG mice
Three days after i.t. tumour inoculation (Figure IA), glioma cells
were frequently observed in the basal cisterns and ventricles and on
the brain surface. Mass formation was observed in the basal cistern
after 8 days (Figure 1B). Hydrocephalus was seen in several mice.
Untreated mice lost body weight, developed paraplegia and were
expected to die within 2 weeks after tumour inoculation.
Intraperitoneal administration of IL-12 was effective in
immunocompetent MG mice but not in T-cell-deficient
MG mice
All untreated MG mice showed MG symptoms described in
Materials and methods within 8 days (Figure 2A, thin solid line). The
symptom-free time was prolonged in MG mice treated with IL-12 at
0.1 tg i.p., and 40% ofthese mice did not reveal any symptoms (P =
0.053; Figure 2A, dashed line) for longer than 30 days. Eighty per
cent of MG mice treated with IL-12 at 0.5 jg i.p. had been without
MG symptoms for longer than 30 days (P < 0.01; Figure 2A, bold
solid line), and they werejudged to be cured. The median symptom-
free time was not prolonged in any of the groups treated i.t. in
comparison with the control group (P > 0.07; Figure 2B), although a
few mice had been without MG symptoms for longer than 30 days in
both the IL-12 at 0.1 and the IL-12 at 0.05-,ug i.t. groups. These
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results showed that the local administration of IL-12 into the CNS
was less effective in vivo than the systemic administration.
In BALB/c-nu/nu mice, in which NK activity is considered to
be strong, all MG mice showed MG symptoms within 9 days both
in the untreated group and in the IL-12 i.p. group (P = 0.17; Figure
3). These findings revealed that i.p. IL-12 was effective in
immunocompetent MG mice but not effective in T-cell-deficient
MG mice. Furthermore, NK cells alone, without T cells, may not
be capable ofrejecting tumour cells transplanted into the CNS.
CD4+ and CD8+ lymphocytes primarily infiltrated the
tumour-bearing areas of MG mice after IL-12 treatment
Tumour formation and hydrocephalus were observed in brain
sections ofuntreated mice, with tumour masses daily increasing in
size (Figure 1). Few lymphocytes were present in or around the
tumours of untreated mice (Figure 4A). In the MG mice treated
with IL-12 i.p., tumours gradually increased in size from day 4 to
day 6, but then became smaller on day 8, and no tumours were
found on day 16 (data not shown). TIL and some necrotic regions
were observed on day 6 in tumour areas of the MG mice treated
with IL-12 i.p. (Figure 4B). These lymphocytes consisted mostly
ofCD4+ and CD8+ cells (Figure 4C and D), in a respective ratio of
approximately 0.4-0.6. These results indicated that i.p. adminis-
tration of IL-12 stimulates CD4+ and CD8+ lymphocytes to infil-
trate into and around the tumours of MG mice.
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Figure 5 T lymphocyte populations in CLN and spleen of MG mice treated with i.p. IL-12 from days 3 to 7 (grey bars) and from days 3 to 13 (white bars)
and of untreated controls (black bars). (A-C) Total numbers of CD3-, CD4- and CD8-positive lymphocytes, respectively, in the spleens. (D-F) Total numbers
of CD3-, CD4- and CD8-positive lymphocytes, respectively, in the CLN. Bars indicate standard error (s.e.). Statistical evaluation by Student's t-test. *P< 0.05,
**P < 0.01
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Figure 6 IFN-y and IL-10 production by lymphocytes in CLN and spleen of MG mice receiving IL-12 from days 3 to 7 (grey bars) and of untreated controls
(black bars). Lymphocytes (106) were incubated in 250 pl of medium for 48 h and each cytokine was measured using an ELISA kit. (A) Concentration of IFN-y
produced by splenocytes. (B) Concentration of IL-10 produced by splenocytes. (C) Concentration of IFN-y produced by CLN lymphocytes. (D) Concentration of
IL-10 produced by CLN lymphocytes. Bars indicate s.e. Statistical evaluation by Student's t-test. *P < 0.05, **P < 0.01, ND not detected
Numbers of CD3-, CD4- and CD8-positive T
lymphocytes in CLN significantly increased in
IL-12-treated MG mice
IL-12 did not have a significant effect on the cell distribution
(CD3, CD4 and CD8) in the spleen and CLN ofMG mice (data not
shown). However, because the spleen and CLN were enlarged in
i.p. IL-12-treated MG mice, the total number of T lymphocytes
also increased as a natural consequence. Although the total
numbers of CD3 (Figure SA), CD4 (Figure 5B) and CD8 cells
(Figure 5C) in the spleen ofi.p. IL- 12-treated MG mice (grey bars)
were larger than in untreated mice (black bars), the increase was
not statistically significant. T-cell population in the CLN ofi.p. IL-
12-treated MG mice significantly increased in comparison with
untreated MG mice (Figures 5D-F). These MG models were then
administered IL-12 i.p. from days 3 to 13 to compare the results
with those in the mice treated for 5 days. Prolonged IL-12 treat-
ment did not further affect the T-cell markers (Figure 5, white
bars). Each T-cell population showed a maximum on day 8 in the
spleen and on day 4 in the CLN.
IFN-y production by lymphocytes in the CLN was
markedly increased in IL-12-treated MG mice
We examined IFN-y and IL-10 production by lymphocytes in the
CLN and spleen in MG mice with or without IL-12 treatment. The
splenocytes obtained from i.p. IL-12-treated MG mice secreted the
same level of IFN-y as those from untreated mice (Figure 6A). On
the other hand, a significant increase in IFN-y was consistently
observed in the lymphocytes derived from the CLN of i.p. IL-12-
treated MG mice (Figure 6C). Although the splenocytes from
treated MG mice secreted less IL- 10 on days 6 and 8 than those
from untreated mice (Figure 6B), the lymphocytes in the CLN
obtained from treated MG mice secreted more IL- 10 on days 4 and
6 than those from untreated mice (Figure 6D). In treated MG mice,
lymphocytes from the CLN maintained a high level of IFN-y
secretion until day 6 and then production decreased on day 8, but
IL- 10 production was already decreased on day 6 (Figs 6C and D
grey bars).
MG mice cured by IL-12 rejected rechallenge with
glioma cells
MG mice cured by IL-12 and surviving more than 8 weeks after
the first inoculation ofglioma cells were reinoculated with 5 x 106
glioma cells injected into the cisterna magna. These survivors had
shown no MG symptoms without any treatment for more than 8
weeks after reinoculation with glioma cells (P < 0.01; Figure 7A).
Apparent tumours were observed s.c. after 1 week when 1 x 107
glioma cells were inoculated s.c. into untreated mice (Figure 7B,
black squares), but MG mice cured by IL-12 rejected these s.c.
inoculated glioma cells completely (P < 0.01; Figure 7B, black
circles). Syngeneic C3H/MCA clone 15 fibrosarcoma cells,
however, grew s.c. larger in cured MG mice (Figure 7B, white
circles).
British Journal ofCancer (1998) 78(4), 446-453
A
Day 4
Day6
B
Day 8
0
to .5 0
0
A._
0
Cu
0
Spleen
C - I ]*
Day4
300 0
Day4
Day 6
Day 8
800 -1 -1
0 CancerResearch Campaign 1998
I **Anti-tumour activity ofIL-12 in the CNS 451
' Tj I I I
- s --
5 10 15 20 25 30 35 40 45 50 0 5 10 15 20 25 30
Days after tumour inoculation Days after tumour inoculation
Figure 7 Rejection of the rechallenged glioma cells both intrathecally (A) or subcutaneously (B) in cured MG mice by IL-12. Statistical evaluation by Student's
t-test. *P < 0.01. (A) MG mice cured by intraperitoneal (i.p.) IL-12 were rechallenged with the same RSV-M glioma cells intraperitoneally (i.t.). All reinoculated
MG mice remained without MG symptoms for longer than 8 weeks (bold line), while all MG mice inoculated for the first time had shown MG symptoms within 9
days after a single inoculation (thin line). (B) Growth of subcutaneous (s.c.) transplanted RSV-M glioma cells and C3H/MCA clone 15 fibrosarcoma cells. While
growth of the s.c. transplanted tumour cells was observed in normal mice (black squares), MG mice which had been cured by IL-12 subsequently rejected the
same cells when transplanted s.c. (black circles). C3H/MCA clone 15 fibrosarcoma cells grew up both in cured MG mice (white circles) and in normal mice
(white squares). Bars indicate s.e.
DISCUSSION
In this report, we applied the MG model to investigate the
immunological response against tumour cells in the CNS.
Although the pia mater separates subarachnoid space from brain
parenchyma, some intrathecally injected glioma cells show
parenchymal invasion (Kitamura et al, 1996; unpublished data); in
addition, glioma cells undergo CSF pathway dissemination in
animal models and in patients with advanced glioma (Arita et al,
1994; Yamada et al, 1994). On the other hand, the BBB or the
blood-CSF barrier around the tumour mass in the CNS was
thought to be destroyed, and thus tumour antigens gained access
to the systemic immune system via tumour vessels or
Virchow-Robin space, which continues to subarachnoid space.
Further, it was easy to carry out the MG model on mice, and the
appearance of MG symptoms showed good correlation with the
numbers of intrathecally injected tumour cells. In this way, we
used the MG model to investigate the anti-tumour efficacy of
IL-12 in the CNS.
In this paper, we have demonstrated that systemic administra-
tion ofIL-12 was surprisingly effective against malignant tumours
in the subarachnoid space of the CNS (MG mice). As previously
reported (Tahara et al, 1994), IL-12 does not directly affect the
growth ofRSV-M glioma cells in vitro (data not shown). However,
systemic IL-12 prolonged the symptom-free time in the present
study (P < 0.01; Figure 2A). Not only systemic administration but
also local or peritumoral injection of IL-12 has been reported to
induce the regression of some subcutaneous tumours (Brunda et al,
1993; Tahara et al, 1994). Although i.t. IL-12 treatment was less
effective when judged on the basis of the median symptom-free
time (P > 0.07; Figure 2B), some MG mice were nevertheless
cured by i.t. administration. A large i.t. dose of IL-12 may have
some toxicity because some normal mice had lost body weight
during and after i.t. administration of 0.5 jg of IL-12 (data not
shown). As treatment with IL-12 at 0.5 ,ug i.t. induced
splenomegaly, as did i.p. treatment (data not shown), i.t. IL-12
would affect systemic immunity. These findings suggest that i.t.
injection ofIL-12 has some anti-tumour effect, but that its toxicity
offsets its efficacy. Thus, systemic IL-12 may be the preferable
choice even for the treatment ofCNS tumours.
Under normal conditions, no lymphocytes are present in the
brain parenchyma. TIL, however, are found in and around the
tumours in 35-80% of glioma patients (de Micco, 1989). B
lymphocytes and NK cells do not play major roles in suppressing
the growth of human gliomas (Sawamura et al, 1988). TIL are
activated by IL-12 in vitro (Andrews et al, 1993), and IL-12 can
induce the production of CD8+ CTL in vitro (Bloom et al, 1994).
Large numbers of TIL were observed in immunocompetent MG
mice treated with IL-12 (Figure 4), and IL-12 did not show anti-
tumour activity in T-cell-deficient mice (P = 0.17; Figure 3). RSV-
M glioma cells were rejected when they were reinoculated i.t. or
s.c. into MG mice cured by IL-12 (P < 0.01; Figure 7), but
syngeneic C3H/MCA clone 15 fibrosarcoma cells were not
rejected (Figure 7). These findings indicate that tumour-specific
immunity is induced systemically and/or in the CNS of MG mice
cured by IL-12, and that T lymphocytes produced as a result of
activation by IL-12 act as major anti-tumour effectors in MG mice.
Many tumour antigens in the CNS are mainly phagocytized by
microglia (Shrikant et al, 1996), and a significant percentage ofthe
CSF drains into the CLN (Kida et al, 1993, 1995; Cserr et al,
1992). In MG models, tumour antigens would reach the CLN via
this route. In the CLN, APC activate Th cells and CTL, and they
secrete a moderate amount of IFN-y. Systemic administration of
IL-12 also activates Thl cells and CTL (Seder et al, 1993;
Kennedy et al, 1994; Nastala et al, 1994). In the CLN from IL-12-
treated MG mice, a large number of T lymphocytes and a high
level of IFN-y production were detected (Figures 5 and 6). IFN-y
production by lymphocytes in the CLN from IL-12-treated MG
mice was markedly increased (P < 0.01; Figure 6C), and it was
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higher than that in the CLN from normal mice treated with IL-12
(data not shown). These findings suggest that both systemic IL-12
and tumour antigens are necessary for a high level ofIFN-,y secre-
tion. The expression ofMHC antigens can be induced in both glial
and glioma cells in the CNS by IFN-y(Wong et al, 1984; de Micco,
1989; Tamura et al, 1989). Activated glial cells produce granulo-
cyte-macrophage colony-stimulating factor (Ohno et al, 1990; Lee
et al, 1994), and this factor activates microglia, which are one type
of APC in the CNS (Frei et al, 1987; Matsumoto et al, 1992;
Shrikant et al, 1996). In this way, although it has been thought that
the presence of the BBB and the absence of lymphatic tissues
segregate the CNS from systemic immunity, the immune system
would appear to recognize the tumour antigens in the subarachnoid
space of the CNS, and IL-12 may activate immunological reac-
tions against tumours in the CNS. Furthermore, Th cells and CTL
also efficiently infiltrate tumours in the CNS.
Although it is well known that IL-12 stimulates T and NK cells
to secrete IFN-y, there is relatively little information on the effect
of IL-12 on T cells for production of IL-10. It has been reported
that in vivo treatment of IL-12 increases in both IFN-y and IL-1O
mRNA and that the presence of IL-12 results in an efficient
priming of the clones for high production ofboth IFN-y and IL-10
(Finkelman et al, 1994; Gerosa et al, 1996). In the present study,
both IFN-y and IL-10 production elevated on days 4 and 6 in the
CLN from IL-12 treated MG mice (Figure 6D). Elevation of IL-10
is supposed to affect an anti-inflammatory response involving
down-regulation of Thl (Gerosa et al, 1996). Some investigators
have, however, reported that production of IL-10 in bulk T-cell
cultures stimulated in vitro with allergen is inhibited if IL-12 is
added to the cultures (Marshall et al, 1995). The other investiga-
tors have reported that the IL-10-producing clone is primed only if
IL-12 is added to the culture in the first few days (Gerosa et al,
1996). In this study, IL-10 levels of the CLN decreased by day 6
and were not detected on day 8, while IFN-y production was still
maintained at a high level on day 6 and present on day 8 (Figures
6C and D). The release of the hyperimmune state and/or the
prolonged stimulation of IL-12 might result in the decrease of
IL-10 level preceding that of IFN-y level.
The results ofthis study indicate that systemic IL-12 administra-
tion induces T-lymphocyte-mediated immune responses in the
CNS, and that CTL appear to play an important role in the rejec-
tion ofglioma cells in the CNS. Furthermore, IL-10 secretion may
suppress such inflammatory functions in these models.
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